Case Study | Published:

Treatment of male infertility secondary to morbid obesity

Nature Clinical Practice Endocrinology & Metabolism volume 4, pages 415419 (2008) | Download Citation


Background A 29-year-old man presented to a clinic with infertility and hypogonadism in the setting of morbid obesity. On presentation, he had notable gynecomastia and a low testicular volume. The patient's weight was 154 kg and his height was 168 cm (BMI 54.5 kg/m2). Before referral to the clinic, the patient had been treated with testosterone therapy for 4 months for hypogonadism. This treatment had caused his initially low sperm concentration to fall to undetectable levels.

Investigations Measurement of reproductive hormone levels, pituitary MRI, and semen analysis.

Diagnosis Infertility secondary to hypogonadotropic hypogonadism and an elevated estrogen:testosterone ratio.

Management Treatment with an aromatase inhibitor, anastrozole, led to normalization of the patient's testosterone, luteinizing hormone and follicle-stimulating hormone levels, suppression of serum estradiol levels, and to normalization of spermatogenesis and fertility.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    et al. (2006) Obesity and male reproductive potential. J Androl 27: 619–626

  2. 2.

    and (2002) Aromatase inhibitors for male infertility. J Urol 167: 624–629

  3. 3.

    et al. (1985) Population study of causes, treatment, and outcome of infertility. Br Med J (Clin Res Ed) 291: 1693–1697

  4. 4.

    et al. (2004) Body mass index in relation to semen quality and reproductive hormones among 1,558 Danish men. Fertil Steril 82: 863–870

  5. 5.

    et al. (2004) Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 291: 2847–2850

  6. 6.

    et al. (2007) Is overweight a risk factor for reduced semen quality and altered serum sex hormone profile? Fertil Steril [doi:10.1016/j.fertnstert.2007.07.1292]

  7. 7.

    et al. (2006) Reduced fertility among overweight and obese men. Epidemiology 17: 520–523

  8. 8.

    et al. (2008) Male obesity and alteration in sperm parameters. Fertil Steril. [doi:10.1016/j.fertnstert.2007.10.011]

  9. 9.

    et al. (2007) Men's body mass index and infertility. Hum Reprod 22: 2488–2493

  10. 10.

    et al. (2006) Effect of body weight on testosterone/estradiol ratio in oligozoospermic patients. Arch Androl 52: 97–102

  11. 11.

    et al. (2006) In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion. J Clin Endocrinol Metab 91: 3324–3328

  12. 12.

    et al. (2008) Mass spectrometric and physiological validation of a sensitive, automated, direct immunoassay for serum estradiol using the Architect(R). Clin Chim Acta 388: 99–105

  13. 13.

    et al. (2000) Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 85: 2670–2677

  14. 14.

    et al. (2006) Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 91: 1995–2010

  15. 15.

    et al. (2003) Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52: 1126–1128

  16. 16.

    et al. (2005) Letrozole normalizes serum testosterone in severely obese men with hypogonadotropic hypogonadism. Diabetes Obes Metab 7: 211–215

Download references


The authors thank WJ Bremner for helpful comments during the preparation of the manuscript. ST Page is supported, in part, by the National Institute of Aging, a Division of the NIH, by grant K23 AG027238. JK Amory is supported, in part, by the National Institute of Child Health and Human Development, a Division of the NIH, through grant K23 HD45386.

Author information


  1. MY Roth is a Senior Fellow at the Division of Metabolism, Endocrinology and Nutrition, JK Amory is an Associate Professor of Medicine and ST Page is an Assistant Professor of Medicine, all at the University of Washington School of Medicine, Seattle, WA, USA.

    • Mara Y Roth
    • , John K Amory
    •  & Stephanie T Page


  1. Search for Mara Y Roth in:

  2. Search for John K Amory in:

  3. Search for Stephanie T Page in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Stephanie T Page.

About this article

Publication history





Further reading